Last $22.57 USD
Change Today -0.57 / -2.46%
Volume 376.9K
NUVA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/22/13 All times are local (Market data is delayed by at least 15 minutes).

nuvasive inc (NUVA) Snapshot

Open
$23.12
Previous Close
$23.14
Day High
$23.55
Day Low
$22.42
52 Week High
07/5/12 - $25.99
52 Week Low
10/23/12 - $12.35
Market Cap
998.3M
Average Volume 10 Days
330.7K
EPS TTM
$0.38
Shares Outstanding
44.2M
EX-Date
--
P/E TM
59.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for NUVASIVE INC (NUVA)

Related News

No related news articles were found.

nuvasive inc (NUVA) Related Businessweek News

No Related Businessweek News Found

nuvasive inc (NUVA) Details

NuVasive, Inc., a medical device company, engages in the design, development, and marketing of minimally disruptive surgical products and procedurally integrated solutions for the spine. The company’s products focus on applications for spine fusion surgery. It offers products for the thoracolumbar spine and the cervical spine primarily used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s principal products include a minimally disruptive surgical platform called Maximum Access Surgery (MAS), as well as cervical, biologics, and motion preservation products. Its MAS platform combines three categories of product offerings, including NVM5 and NVJJB, its proprietary software-driven nerve detection and avoidance systems, and intra-operative monitoring support services for insight into the nervous system during spine and other surgeries; MaXcess, an integrated split-blade retractor system; and various specialized implants. The company’s biologic products include allograft, a donated human tissue; FormaGraft, a collagen synthetic product; Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells; and AttraX, a synthetic bone graft material. It also offers solutions for cervical fusion surgery, including allograft and CoRoent implants, as well as cervical plating and posterior fixation products. In addition, the company’s products comprise PCM device, a motion preserving total disc replacement device; and XL TDR, a mechanical total disc replacement solution. NuVasive, Inc. sells its products through directly-employed sales shareowners, independent sales agents, and distributors to surgeons and hospitals in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.

1,173 Employees
Last Reported Date: 02/27/13
Founded in 1997

nuvasive inc (NUVA) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $900.0K
President and Chief Operating Officer
Total Annual Compensation: $550.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $482.5K
President of Global Products & Services
Total Annual Compensation: $520.0K
Compensation as of Fiscal Year 2012.

nuvasive inc (NUVA) Key Developments

NuVasive, Inc. Presents at Mizuho Healthcare Access Day, May-07-2013

NuVasive, Inc. Presents at Mizuho Healthcare Access Day, May-07-2013 . Venue: New York, New York, United States.

NuVasive, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2013; Revises Earnings Guidance for the Full Year 2013

NuVasive, Inc. announced unaudited consolidated earnings results for the first quarter ended march 31, 2013. For the period, revenue was $159,504,000 against $151,691,000 in the same period a year ago. Interest income was $172,000 against $208,000 in the same period a year ago. Loss before income taxes was $168,000 against income before income taxes of $1,066,000 in the same period a year ago. Net income was $596,000 against $469,000 in the same period a year ago. Net income attributable to the company was $851,000 or $0.02 per basic and diluted share against $673,000 or $0.02 per basic and diluted share against in the same period a year ago. Net cash provided by operating activities was $24,106,000 against $39,740,000 in the same period a year ago. Purchases of property and equipment were $9,200,000 against $14,567,000 in the same period a year ago. Non-GAAP net income was $11,900,000 or $0.26 per share. The company revises earnings guidance for the full year 2013. The company expects revenue of approximately $655 million, unchanged from prior guidance. GAAP EPS of approximately $0.02, compared to $0.07 previous guidance. Non-GAAP EPS of approximately $1.00, unchanged from prior guidance Non-GAAP Operating Margin of approximately 14%, unchanged from prior guidance GAAP effective tax expense rate of approximately 80%, compared to 60% previous guidance.

NuVasive, Inc. Announces New Office Opening in Japan; Appoints Takaaki Tanaka as Head of its The Tokyo Office

NuVasive, Inc. announced the official opening of its Tokyo, Japan office, which will strengthen the company's ability to bring game-changing products, procedures, and services to the spine market in the world. The company announced that The Tokyo office will be headed by NuVasive's Executive Vice President of Asia Pacific, Takaaki Tanaka.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NUVA:US $22.57 USD -0.57

NUVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArthroCare Corp $33.33 USD -1.06
CONMED Corp $33.28 USD +0.04
ICU Medical Inc $68.16 USD -0.38
Integra LifeSciences Holdings Corp $36.50 USD -0.44
Wright Medical Group Inc $23.66 USD -0.86
View Industry Companies
 

Industry Analysis

NUVA

Industry Average

Valuation NUVA Industry Range
Price/Earnings 100.0x
Price/Sales 1.6x
Price/Book 1.9x
Price/Cash Flow 59.1x
TEV/Sales 0.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVASIVE INC, please visit www.nuvasive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.